Benefits
Improvement of metabolic syndrome components
Hidalgo-Lozada 2022 RCT (PMID 36233611, n=32) showed 12 weeks of 500 mg twice daily ellagic acid in patients with metabolic syndrome reduced: waist circumference (-2.5 cm vs +0.2 cm placebo, p=0.001), systolic BP (-4.9 vs -0.1 mmHg, p=0.011), diastolic BP (-3.1 vs -0.4 mmHg, p=0.013), fasting glucose (-0.8 vs +0.2 mmol/L, p=0.001), triglycerides (-0.7 vs +0.5 mmol/L, p=0.001), and improved insulin sensitivity (Matsuda index +1.4 vs -0.2, p=0.001).
Type 2 diabetes glycemic control
Ghadimi 2021 (PMID 32909365) — 8-week double-blind RCT in patients with T2D showed ellagic acid + metformin reduced fasting glucose, HbA1c, HOMA-IR, and improved antioxidant markers (SOD, CAT) and inflammatory markers (TNF-α, IL-6) vs metformin + placebo. Established complementary role to metformin.
PCOS insulin sensitivity and androgen reduction
Kazemi 2021 (PMID 34330312) — 8-week double-blind RCT in women with polycystic ovary syndrome showed ellagic acid (200 mg/day) reduced fasting insulin, HOMA-IR, total testosterone, free androgen index, and improved oxidative stress markers vs placebo. Useful adjunct for the metabolic component of PCOS.
Lipid profile and antioxidant effects
The 2024 Wang et al meta-analysis of 10 RCTs showed pooled ellagic acid effects: reduced fasting blood glucose (p=0.008), increased insulin secretion (p=0.01), improved HOMA-IR (p=0.003), decreased triglycerides (p=0.004), total cholesterol (p=0.04), and LDL-c (p=0.0004). Effect sizes are modest but consistent.
Mechanism of action
Urolithin conversion (gut microbial bioactivation)
Ellagic acid itself has very low bioavailability (~1%). Gut bacteria — particularly Gordonibacter species — convert ellagic acid (and ellagitannins like punicalagin) into urolithin A, urolithin B, and isourolithin A through stepwise dehydroxylation. Urolithins are absorbed and reach plasma concentrations of 0.2-20 μM. Individuals show three urolithin metabotypes (A, B, 0) based on microbiome composition — explaining why some respond and others don't.
AMPK activation and GLUT-4 translocation
Ellagic acid (Poulose et al) activates AMP-activated protein kinase and ERK signaling, increasing GLUT-4 translocation in skeletal muscle and adipose tissue. This explains the improvement in fasting glucose and insulin sensitivity observed across multiple human RCTs.
Resistin suppression and adipogenesis inhibition
Ellagic acid suppresses adipocyte secretion of resistin (Makino-Wakagi 2012 PMID 22206671) — an adipocytokine that drives insulin resistance. Concurrently, ellagic acid inhibits 3T3-L1 preadipocyte differentiation by interrupting Rb phosphorylation and the cell cycle. These mechanisms explain effects on abdominal obesity and metabolic parameters.
eNOS upregulation (blood pressure mechanism)
Berkban 2015 (PMID 26133972, rat L-NAME hypertension model) demonstrated ellagic acid restores endothelial nitric oxide synthase expression and reduces p47phox (NADPH oxidase). This produces blood pressure reduction in hypertensive — but not normotensive — animals, explaining the BP reductions observed in the Hidalgo-Lozada human MetS trial.
Clinical trials
Randomized, double-blind, placebo-controlled clinical trial (Hidalgo-Lozada GM, Villarruel-López A, Martínez-Abundis E, Vázquez-Paulino O, González-Ortiz M, Pérez-Rubio KG 2022, J Clin Med 11(19):5741, doi:10.3390/jcm11195741).
32 adults aged 30-59 with metabolic syndrome diagnosis (International Diabetes Federation criteria). Randomized to ellagic acid (500 mg pomegranate extract, 90% EA) twice daily or placebo (calcined magnesia) for 12 weeks. 30 completed analysis (15 per arm).
Ellagic acid significantly improved all assessed metabolic syndrome components vs placebo: waist circumference (males -3.8 cm, females -2.7 cm, p<0.05), systolic BP (-4.9 mmHg, p=0.011), diastolic BP (-3.1 mmHg, p=0.013), fasting glucose (-0.8 mmol/L, p=0.001), triglycerides (-0.7 mmol/L, p=0.001), insulin sensitivity (Matsuda index +1.4, p=0.001), insulin secretion (Stumvoll first-phase, p=0.011), and HDL-c in males (p=0.002). Body weight reduced 1.5 kg (p=0.001) and uric acid -20.6 µmol/L (p=0.002). No serious adverse events; AST/ALT/creatinine unchanged.
Randomized double-blind clinical trial (Ghadimi M, Foroughi F, Hashemipour S, Nooshabadi MR, Ahmadi MH, Nezhad BA, Haghighian HK 2021, Phytother Res 35(2):1023-1032, doi:10.1002/ptr.6867).
Patients with type 2 diabetes treated with metformin. Randomized to ellagic acid + metformin or placebo + metformin.
Ellagic acid supplementation significantly reduced fasting blood glucose, HbA1c, insulin levels, and HOMA-IR vs placebo. Antioxidant capacity increased (SOD, CAT, GPX) and inflammatory markers decreased (TNF-α, IL-6). Established complementary role to metformin in T2D management with improvements in both glycemic and inflammatory parameters.
Randomized double-blind clinical trial (Kazemi M, Lalooha F, Nooshabadi MR, Dashti F, Kavianpour M, Haghighian HK 2021, J Ovarian Res 14(1):100, doi:10.1186/s13048-021-00849-2).
Women with polycystic ovary syndrome (PCOS) randomized to ellagic acid 200 mg/day or placebo for 8 weeks.
Ellagic acid significantly reduced fasting insulin, HOMA-IR, total testosterone, free androgen index, malondialdehyde (oxidative stress) vs placebo. Total antioxidant capacity, SOD, and GPX activity increased. Established a role for ellagic acid in addressing both metabolic (insulin resistance) and androgenic components of PCOS.
About this ingredient
Ellagic acid (EA; IUPAC: 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione) is a tetrahydroxylated polyphenolic dilactone formed when two molecules of gallic acid undergo oxidative coupling. In foods, EA exists primarily as part of larger ellagitannins (punicalagin, punicalin in pomegranate; sanguiin H-6, lambertianin C in raspberries; pedunculagin in walnuts and oak). These ellagitannins hydrolyze in the upper GI tract to release EA, which is then converted by gut microbiota to urolithins (especially urolithin A) — the actually bioavailable forms.
Top dietary sources: pomegranate (fruit and juice), walnuts, pecans, raspberries, blackberries, strawberries, oak-aged wines, and certain teas. Commercial supplements range from 50-500 mg per capsule, often as pomegranate extract standardized to 40-90% EA. Three urolithin metabotypes exist in humans: UM-A (produces urolithin A and B), UM-B (produces urolithin B, isourolithin A, and urolithin A), UM-0 (non-producer, ~10% of the population).
UM-0 individuals are unlikely to benefit from ellagic acid supplementation — direct urolithin A supplementation (e.g., Mitopure®) bypasses this. EVIDENCE: Three published human RCTs in metabolic conditions form the strongest base — Hidalgo-Lozada 2022 (n=32 metabolic syndrome), Ghadimi 2021 (T2D), Kazemi 2021 (PCOS). Plus the Wang 2024 meta-analysis of 10 RCTs confirming consistent metabolic benefits (FBG, HOMA-IR, triglycerides, total cholesterol, LDL-c).
3/5 evidence rating reflects strong mechanistic case + multiple RCTs but small sample sizes (typically 30-80 per trial) and most trials in specific patient populations (T2D, MetS, PCOS) rather than healthy adults. SAFETY: Very good tolerability across published trials. Most pomegranate-derived products are GRAS.
The bioavailability bottleneck (urolithin conversion variability) is the major practical limitation — not all individuals will respond. Best positioned as a metabolic support adjunct for those with metabolic syndrome, T2D, PCOS, or related conditions, ideally taken with food and as part of a polyphenol-supportive diet that promotes UM-A metabotype microbiome composition.